• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stem Cells

Elutia raises $26M for drug-eluting biomatrix tech

September 19, 2023 By Sean Whooley

Elutia Logo

Elutia (Nasdaq:ELUT) announced today that it entered into a securities purchase agreement worth total proceeds of $26.2 million. The drug-eluting biomatrix company expects the private placement financing to result in initial gross proceeds of approximately $10.5 million. The full exercise of warrants would add $15.8 million to reach a total of $26.2 million. Silver Spring, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Implants, Regenerative Medicine, Stem Cells Tagged With: Elutia

CellTrans wins FDA approval for first cell therapy that treats type 1 diabetes

June 30, 2023 By Sean Whooley

CellTrans

The FDA announced that it approved the Lantidra allogeneic pancreatic islet cellular therapy developed by CellTrans to treat diabetes. It marks the first approval of a donor pancreatic cellular therapy — made from deceased donor pancreatic cells — to treat type 1 diabetes. The approval covers adults with type 1 diabetes who prove unable to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Stem Cells Tagged With: CellTrans, FDA

Lilly to acquire Sigilon, cell therapy for treating diabetes

June 29, 2023 By Sean Whooley

Eli Lilly Sigilon logo

Eli Lilly (NYSE:LLY) announced today that it entered a definitive agreement to acquire biopharmaceutical company Sigilon. Cambridge, Massachusetts-based Sigilon seeks to develop functional cures for patients with a range of acute and chronic diseases. The two companies have collaborated since 2018 to develop encapsulated cell therapies, including SIG-002. These therapies aim to treat type 1 […]

Filed Under: Business/Financial News, Diabetes, Featured, Mergers & Acquisitions, Pharmaceuticals, Stem Cells Tagged With: Eli Lilly, Eli Lilly & Co., sigilontherapeutics

Sernova, AstraZeneca collaborate to deliver therapeutic cells with Sernova Cell Pouch

May 3, 2023 By Sean Whooley

Sernova Cell Pouch System Type 1 Diabetes

Sernova announced today that it entered into a preclinical research collaboration on drug delivery with AstraZeneca. The collaboration aims to evaluate the use of Sernova’s Cell Pouch System in combination with AstraZeneca’s novel therapeutic cells. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Preclinical Trials, Stem Cells Tagged With: AstraZeneca plc, Sernova Inc

Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte for $320M

July 11, 2022 By Sean Whooley

Vertex Pharmaceuticals ViaCyte

Vertex Pharmaceuticals (Nasdaq:VRTX) announced today that it agreed to acquire ViaCyte for $320 million. San Diego-based ViaCyte develops an advanced portfolio of novel stem cell-derived replacement therapies designed to provide a functional cure for patients with type 1 diabetes. Boston-based Vertex develops its own similar therapeutic for diabetes, having designed its VX-880 as a stem […]

Filed Under: Business/Financial News, Diabetes, Featured, Mergers & Acquisitions, Stem Cells Tagged With: Vertex Pharmaceuticals, ViaCyte

FDA grants breakthrough nod to Zetagen’s metastatic bone cancer treatment

December 1, 2021 By Sean Whooley

Zetagen Logo

Zetagen Therapeutics announced today that it received FDA breakthrough device designation for its ZetaMet cancer treatment technology. Syracuse, New York-based Zetagen designed its ZetaMet (previously known as ZetaFuse) as a synthetic, small-molecule, inductive biologic technology for targeting and resolving metastatic bone lesions while inhibiting future tumor growth and regenerating bone. According to a news release, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regenerative Medicine, Stem Cells Tagged With: FDA, Zetagen Therapeutics

Magenta Therapeutics rises on Street-beating Q4

March 3, 2021 By Sean Whooley

Magenta Therapeutics

Magenta Therapeutics (NSDQ:MGTA) shares ticked up today on fourth-quarter earnings that topped the consensus forecast. The Cambridge, Mass.-based stem cell transplantation technology developer posted losses of -$18.2 million, or -38¢ per share for the three months ended Dec. 31, 2020, marking a 21.8% bottom-line gain. Magenta’s earnings per share of -38¢ came in 3¢ ahead […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Stem Cells, Wall Street Beat Tagged With: magentatherapeutics

Frequency Therapeutics registers $100m IPO

September 9, 2019 By Sean Whooley

Frequency Therapeutics updated logo

Frequency Therapeutics has registered an initial public offering of common stock worth $100 million. Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units. The company applied to the Securities and Exchange Commission have its common stock listed on The Nasdaq Global […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Hydrogels, Initial Public Offering (IPO), Otolaryngology Ear, Nose & Throat, Research & Development, Stem Cells Tagged With: Frequency Therapeutics

AxoSim touts results of nerve-on-a-chip study

July 9, 2019 By Nancy Crotti

AxoSim

A new study of AxoSim’s Nerve-on-a-Chip technology shows that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders. The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. […]

Filed Under: Featured, Neurological, Research & Development, Stem Cells Tagged With: AxoSim

Anika collabs to develop injectable stem cell therapy for osteoarthritis

February 2, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) has inked an agreement with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy to treat osteoarthritis. As a result of the three-year research collaboration, the group hopes to have a lead candidate that it can take into clinical trials. “We are very excited […]

Filed Under: Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Stem Cells, Wall Street Beat Tagged With: Anika Therapeutics Inc., University of Liverpool

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS